Cefalexin

Lore & Background

It is available as a generic medication and is on the World Health Organization's List of Essential Medicines. Cefalexin can treat certain bacterial infections, including those of the middle ear, bone and joint, skin, and urinary tract. It may also be used for certain types of pneumonia and strep throat and to prevent bacterial endocarditis. Cefalexin is not effective against infections caused by methicillin-resistant Staphylococcus aureus (MRSA), most Enterococcus, or Pseudomonas. Like other antibiotics, cefalexin cannot treat viral infections, such as the flu, common cold or acute bronchitis. Common side effects include stomach upset and diarrhea. Allergic reactions or infections with Clostridioides difficile, a cause of diarrhea, are also possible. Use during pregnancy or breastfeeding does not appear to be harmful to the fetus. It can be used in children and those over 65 years of age. Those with kidney problems may require a decrease in dose.

Reader's Guide

Cefalexin is a widely used oral antibiotic belonging to the first-generation cephalosporin class. Its significance lies in its effectiveness against a range of common bacterial infections, including those of the middle ear, bone and joint, skin, and urinary tract, as well as certain types of pneumonia and strep throat. It also serves as a preventive agent for bacterial endocarditis. As a β-lactam antibiotic, it works by disrupting bacterial cell wall synthesis. A key advantage is its oral administration, which allows for outpatient treatment, unlike some other first-generation cephalosporins such as intravenous cefazolin. Cefalexin is a useful alternative for patients with mild or moderate penicillin allergies, though caution is advised due to possible cross-sensitivity. Its legacy is reflected in its inclusion on the World Health Organization's List of Essential Medicines and its consistent high prescription rates in multiple countries. However, its limitations are notable: it is ineffective against MRSA, most Enterococcus, Pseudomonas, and all viral infections. The development of bacterial resistance, particularly via β-lactamase enzymes, remains a concern. Overall, cefalexin remains a foundational antibiotic in primary care and hospital settings.

Did You Know?

• It is on the World Health Organization's List of Essential Medicines.
• Cefalexin is not effective against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
• More than 90% of cefalexin is excreted unchanged in the urine within 8 hours.

Molecular Mechanism & Pharmacokinetic Profile

Cefalexin belongs to the first-generation cephalosporin class of β-lactam antibiotics, sharing a close pharmacological relationship with intravenous cefazolin while offering the practical advantage of oral administration. Its bactericidal action centers on the bacterial cell wall: the molecule structurally mimics d-alanyl-d-alanine, the terminal amino acid sequence of the peptidoglycan layer, allowing it to lock irreversibly into the active site of penicillin-binding proteins that are indispensable for wall synthesis. This makes it particularly potent against gram-positive cocci, with only moderate reach into certain gram-negative bacilli. A critical vulnerability is the β-lactamase enzyme produced by some bacteria, which cleaves the β-lactam ring and neutralizes the drug, a key driver of emerging resistance. Pharmacokinetically, cefalexin is absorbed rapidly and nearly completely from the gut, reaching peak plasma concentrations roughly one hour after a dose. The drug is neither metabolized nor inactivated by the body; instead, over ninety percent is eliminated unchanged in urine within eight hours, with a half-life of thirty to sixty minutes in individuals with normal kidney function. Probenecid, by competing for renal tubular secretion, can slow this clearance.

Clinical Applications & Therapeutic Boundaries

Cefalexin occupies a broad but clearly delineated therapeutic niche in modern medicine. Clinicians prescribe it for middle-ear infections, streptococcal throat infections, bone and joint infections, cellulitis, certain pneumonias, and urinary-tract infections, and it also serves as prophylaxis against bacterial endocarditis and recurrent UTIs. A particularly important role is as a substitute for penicillin in patients who cannot tolerate that drug, though cross-sensitivity among β-lactam antibiotics has been documented in up to ten percent of individuals with a confirmed penicillin allergy, so caution remains essential. The drug is explicitly not recommended for those with severe penicillin hypersensitivity. Its spectrum has firm limits: it is ineffective against methicillin-resistant Staphylococcus aureus, the majority of Enterococcus species, and Pseudomonas, and like all antibiotics it has no activity against viral pathogens responsible for influenza, the common cold, or acute bronchitis. A web of drug interactions further shapes its use—probenecid, dofetilide, warfarin, cholestyramine, live cholera vaccine, alcohol, metformin, H2-receptor antagonists, and zinc supplements all alter its absorption, clearance, or efficacy in clinically meaningful ways.

Safety Profile & Considerations in Special Populations

The most frequently reported adverse effects of cefalexin mirror those of other oral cephalosporins: gastrointestinal upset, with diarrhea being the single most common complaint, alongside nausea and vomiting. Hypersensitivity manifestations range from skin rashes and urticaria to fever and, in rare instances, anaphylaxis. More serious but uncommon reactions include pseudomembranous colitis linked to Clostridioides difficile overgrowth, unexplained bruising, and jaundice. True cefalexin allergy is rare, affecting fewer than one in a thousand patients, though the incidence rises to one to ten percent among those with a known penicillin allergy. Warning signs of a severe reaction include widespread rash, intense itching, facial swelling, difficulty breathing, or skin that turns red, blisters, swells, or peels. For pregnant and breastfeeding women, the safety record is reassuring: Australian regulatory classification places it in Category A, reflecting the absence of observed fetal harm across many pregnancies, and lactation use is generally considered safe. The drug is appropriate for children and adults over sixty-five, although patients with impaired renal function typically require a reduced dose to avoid accumulation.

Development, Global Reach & Prescription Legacy

Today it is widely available as a generic medication, and the World Health Organization both lists it on its List of Essential Medicines and classifies it as highly important for human medicine—a dual endorsement that underscores its irreplaceable role in global health systems. Its prescription footprint is substantial and geographically diverse. The drug's naming also reflects its international journey: cefalexin serves as both the International Nonproprietary Name and the Australian Approved Name, while cephalexin is the British variant, a small linguistic reminder of how a single molecule travels across regulatory and cultural borders to reach patients worldwide.